Open Access

ARTICLE

Identifying predictors of antispasmodic use following robotic assisted simple prostatectomy

Jessica C. Dai¹, Tara N. Morgan¹, Alaina Garbens¹, Samuel Kusin², Hersh Trivedi², Claus G. Roehrborn¹, Jeffrey C. Gahan¹

1 Department of Urology, UT Southwestern Medical Center, Dallas, Texas, USA
2 UT Southwestern Medical School, Dallas, Texas, USA
Address correspondence to Dr. Jessica C Dai, UT Southwestern Department of Urology, 2001 Inwood Drive, WCB3, Suite 4.886, Dallas, TX 75390 USA

Canadian Journal of Urology 2022, 29(2), 11052-11058.

Abstract

Introduction: Anticholinergic or ß-3 agonist use following robotic simple prostatectomy (RASP) is not well described. We describe rates of antispasmodic use following RASP and identify potential predictors of medication use.
Materials and methods: A retrospective review of all RASP patients from 2/2016 - 1/2020 was conducted. Patients with no preoperative International Prostate Symptom Score (IPSS) were excluded. Demographics, clinical data, and postoperative medication use were collected by electronic medical record review. Multivariable logistic regression analysis using a priori variables was performed to identify independent factors associated with antispasmodic use.
Results: A total of 255 patients underwent RASP at a mean age of 70.0 years ± 7.3 and mean body mass index (BMI) of 28.6 kg/m² ± 5.0. Median preoperative prostate volume was 132.3 cc ± 45.0. Rates of preoperative diabetes, obstructive sleep apnea (OSA), smoking and alcohol use were 19.6%, 6.3%, 3.1%, and 11.8% respectively; 8.6% of patients (n = 22) initiated antispasmodics at a median of 2.5 months (IQR 1.3-4.2) postoperatively. Median duration of antispasmodic use was 6.5 months (IQR 1.7-14.7). Mirabegron was most commonly prescribed (31.8%). On multivariable logistic regression analysis, OSA was independently associated with postoperative antispasmodic use (OR 8.13, 95% CI 2.02-32.67, p = 0.003); 68.8% of OSA patients were treated with continuous positive airway pressure (CPAP). Treatment was not significantly associated with postoperative antispasmodic use (p = 0.61).
Conclusion: Patients with OSA are over 8 times more likely to require antispasmodic medications following RASP in the short term. These patients may benefit from more tailored preoperative counseling.

---

Keywords

---